Gossamer Bio
IPOTransforming the lives of patients with pulmonary arterial hypertension.
Public · San Diego, United States · Founded 2017 · $662.0M raised
- Headquarters
- San Diego, California
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B
- Website
- gossamerbio.com
- Total Funding
- $662.0M
- Last Round
- $212.0M Private EquityJul 2023
- Rounds
- 4
- Type
- Public
About
Gossamer Bio, founded in 2015 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company listed on Nasdaq (GOSS). The company is focused on the development and commercialization of seralutinib, an inhaled kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). Gossamer raised $317 million in its 2019 IPO and has a global collaboration with the Chiesi Group for seralutinib development, providing milestone payments and cost reimbursements.
Summary
Gossamer Bio is a Biotech company based in San Diego, United States, founded in 2017. It has raised $662.0M in total across 4 rounds, most recently a $212.0M Private Equity round in Jul 2023. Investors include Hillhouse Capital, ARCH Venture Partners and Omega Funds.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jul 2023
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...